Recommendation ID
NG245/1
Question

What is the clinical and cost-effectiveness of regular 'fixed-dose' inhaled corticosteroid (ICS) regimens (using SABA [short-acting beta2 agonist] as a reliever) compared with 'as-needed' strategies (for example ICS/formoterol) as the initial standard treatment for asthma in children aged 5 to 11 years?

Any explanatory notes
(if applicable)

For a short explanation of why the committee made this recommendation for research, see the rationale and impact section on medicines for initial management in children aged 5 to 11 .

Full details of the evidence and the committee's discussion are in evidence review P: drug classes for initial asthma management.


Source guidance details

Comes from guidance
Asthma: diagnosis, monitoring and chronic asthma management (BTS, NICE, SIGN)
Number
NG245
Date issued
November 2024

Other details

Is this a recommendation for the use of a technology only in the context of research? No  
Is it a recommendation that suggests collection of data or the establishment of a register?   No  
Last Reviewed 28/01/2025